热门站点| 世界资料网 | 专利资料网 | 世界资料网论坛
收藏本站| 设为首页| 首页

Provisions for Import and Export of Anabolic Agents and Peptide Hormones (Interim)

作者:法律资料网 时间:2024-07-23 00:23:35  浏览:8440   来源:法律资料网
下载地址: 点击此处下载

Provisions for Import and Export of Anabolic Agents and Peptide Hormones (Interim)

State Food and Drug Administration General Administration of Customs of the People’s Republic of China


Provisions for Import and Export of Anabolic Agents and Peptide Hormones (Interim)




(SFDA Decree No. 25)

The Provisions for Import and Export of Anabolic Agents and Peptide Hormones (Interim), adopted by the State Food and Drug Administration, the General Administration of Customs of the People’s Republic of China and the General Administration of Sport of China, is hereby promulgated in the decree sequence number of the State Food and Drug Administration and shall come into force as of September 1, 2006.


Shao Mingli
Commissioner
State Food and Drug Administration

Mou Xinsheng
Minister
General Administration of Customs of the People’s Republic of China

Liu Peng
Minister
General Administration of Sport of China
July 28, 2006





Provisions for Import and Export of Anabolic Agents and Peptide Hormones (Interim)


Article 1 The Provisions are formulated with a view to standardizing the administration of import and export of anabolic agents and peptide hormones in accordance with the Drug Administration Law of the People’s Republic of China, Customs Law of People's Republic of China, Anti-doping Regulations and other relevant laws and administrative regulations.

Article 2 The State adopts license control on the import and export of anabolic agents and peptide hormones.

Article 3 The importer shall apply for the importation of anabolic agents and peptide hormones to the State Food and Drug Administration.

Article 4 For the importation of anabolic agents and peptide hormones for medical purpose, the importers shall submit the following materials:
(1) Application Form for Drug Import;
(2) Copy of the purchasing contract or order form;
(3) Copy of the Import Drug License (or the Pharmaceutical Product License) (original or duplicate);
(4) Copy of the Drug Supply Certificate, Business License for Enterprises as a Legal Person, Qualification Certificate for Import and Export Enterprise (or Foreign Trade Operator Filing and Registration Form) and Organization Code Certificate of the importer; to import drug substance and intermediate preparations including preparations to be repackaged in China for their own needs, drug manufacturers shall submit copies of the Drug Manufacturing Certificate, Corporate Business License and Organization Code Certificate;
(5) Where holders of the Import Drug License (or the Pharmaceutical Product License) entrust other companies to export their drugs, they shall provide the authorization letter for export.

All copies mentioned above should be stamped with the official seal of the importer.

Article 5 For the importation of anabolic agents and peptide hormones for teaching and scientific research purposes, the importers shall submit the following materials:
(1) Application Form for Drug Import;
(2) Copy of the purchasing contract or order form;
(3) Certificates of legitimate qualifications of users in China, calculation basis for the quantity of the drug in use and letter of guarantee issued by the user for legitimate use and management of the drug;
(4) Approval documents for relevant scientific research projects or approval documents of relevant competent authority;
(5) Where entrusted by users for importation, importers shall provide copies of the authorization agreement, the Business License for Enterprises as a Legal Person, Qualification Certificate for Import and Export Enterprise (or Foreign Trade Operator Filing and Registration Form) and Organization Code Certificate of the importers.

All copies mentioned above should be stamped with the official seal of the importer.

Article 6 Where a enterprise in China entrusted by an overseas enterprise for contract manufacturing needs to import anabolic agents and peptide hormones, it shall provide materials required in Items (1), (3) and (5) of Paragraph 1 of Article 5, in addition, official documents to prove recorded by the local (food and) drug regulatory department of the province, autonomous region or municipality directly under the Central Government.

All copies mentioned above should be stamped with the official seal of the importer.

Article 7 The State Food and Drug Administration shall decide whether or not to approve the import within 15 working days after receiving the application for import and the relevant materials. Where the application is approved, the State Food and Drug Administration shall issue the Import License for the drug; where the application is not approved, the State Food and Drug Administration shall give reasons in writing.

Article 8 The importer may declare to the customs of the ports where drug importation is permitted upon presenting the Import License for the drug issued by the State Food and Drug Administration. The customs shall clear the drug in the presence of the Import License for the drug.
The Drug Import Note is not required for import of anabolic agents and peptide hormones.

Article 9 To import anabolic agents and peptide hormones including those sold in China for the first time for medical purpose, the importer shall fill in the Import Drug Clearance Form timely after going through the import formalities and submit the following materials in duplicate to the (food and) drug regulatory department where the port of entry is located, upon presenting the original Import Drug License (or the Pharmaceutical Product License) (original or duplicate) and the original Import License for the drug, to apply for the Notice of Import Drug Port Test:
(1) Copies of the Import Drug License (or Pharmaceutical Product License) (original or duplicate) and the Import License for the drug;
(2) Copies of the Drug Manufacturing Certificate or Drug Supply Certificate, and Copy of the Business License for Enterprises as a Legal Person.
(3) Copy of the certificate of origin;
(4) Copy of the purchasing contract;
(5) Copies of packing list, bill of lading and freight invoice;
(6) Copy of the certificate of analysis;
(7) Format of drug insert sheet, package and label (except for drug substance and intermediate preparation);

All copies mentioned above should be stamped with the official seal of the importer.

Article 10 After checking the received Import Drug Clearance Form and relevant materials, the port (food and) drug regulatory department shall return the original Import Drug License (or Pharmaceutical Product License) (original or duplicate) and the original Import License for the drug to the importer, and send the Notice of Import Drug Port Test, along with a copy of the dossier as prescribed in Article 9 of the Provisions, to the port drug testing institute on the same day.

After receiving the Notice of Import Drug Port Test, the port drug testing institute shall contact the importer within two working days and conduct sampling on the storage site. Upon the completion of the sampling, the mark “sampled” shall be stamped on the back of the first page of the original Import License for the drug, with the seal of sampling institute affixed.

Article 11 Anabolic agents and peptide hormones imported for teaching and research purposes or for the domestic manufacturing contracted by overseas enterprises are exempted from testing.

Article 12 The port (food and) drug regulatory department shall report timely to the State Food and Drug Administration in any of the following circumstances:
(1) The port (food and) drug regulatory department refuses to issue the Notice of Import Drug Port Test in accordance with the provisions in Article 17 of the Provisions for Import Drug (Decree No. 4 of the State Food and Drug Administration and the General Administration of Customs);
(2) The port (food and) drug testing institute refuses the sampling in accordance with the requirements in Article 25 of the Provisions for Import Drug.

The port (food and) drug regulatory department shall take mandatory administrative measures to seal up or seize all the imported drugs within the situations prescribed in the previous paragraph. It shall make the decision of allowing shipping back within seven days from the date of the seal-up or seizure, and inform the importer of applying for the Export License for the drug according to the export procedures for anabolic agents and peptide hormones prescribed in the Provisions and return all the import drugs to the original exporting country.

Where the importer fails to respond or make clear its intention to ship back the drugs within ten days after being informed of the decision, the sealed up or seized drugs shall be destroyed under the supervision of the port (food and) drug regulatory department.

Article 13 For imported anabolic agents and peptide hormones out of specifications upon testing by the port drug testing institute, the importer shall provide a detailed report about the distribution and use of all the imported drugs to the port (food and) drug regulatory department where the importer is located within two days after receiving the Import Drug Test Report.

After receiving the Import Drug Test Report, the port (food and) drug regulatory departments shall take mandatory administrative measures to timely seal up or seize all the drugs and, within seven days, decide whether or not to place the case on file.

Where the importer fails to apply for a retesting within the specified timeline or the result of the retesting is still out of specifications, the port (food and) drug regulatory department shall make the decision of allowing shipping back and notify the importer to apply for the Export License for the drug according to export procedures for anabolic agents and peptide hormones prescribed in the Provisions to return all the imported drugs to the original exporting country. Where the importer fails to respond or make clear its intention to ship back the drugs within ten days from the date of receiving the decision, the drugs shall be destroyed under the supervision of the port (food and) drug regulatory department.

Where the result of retesting is in compliance with the specifications, the port (food and) drug regulatory department shall remove the mandatory administrative measures of seal-up and seizure.

The port (food and) drug regulatory department shall handle the case according to the provisions in Paragraph 2, Paragraph 3 and Paragraph 4 of this Article and report the result to the State Food and Drug Administration, and, at the same time, notify the (food and) drug regulatory departments of provinces, autonomous regions and municipalities directly under the Central Government as well as other port (food and) drug regulatory departments.

Article 14 Where domestic drug manufacturers, distributors and medical institutions purchase imported anabolic agents and peptide hormones, the supplier shall provide copies of the Import Drug License (or Pharmaceutical Product License), the Import License for the drug and the Import Drug Test Report, and affix its official seal to the abovementioned copies.

Article 15 The exporter shall apply for exportation of anabolic agents and peptide hormones to the (food and) drug regulatory department of the province, autonomous region or municipality directly under the Central Government, where it is located, and submit the following materials:
(1) Application Form for Drug Export;
(2) Original import permit (or its copy with notarization) provided by the drug regulatory authority of the importing country or region.
If the importing country or region has no license system in the importation of anabolic agents and peptide hormones, the exporter shall provide the official document (original) of the drug regulatory authority of the importing country or region to prove that the import of the drugs of this type is exempted from the import permit, along with one of the following documents:
a. Original official document (or its copy with notarization) granting import provided by the drug regulatory authority of the importing country or region;
b. Certificates of legitimate qualifications of importers and original supporting document (or its copy with notarization) proving legitimate use of the drug;
(3) Copy of the purchasing contract or order form (except for manufacturers that export their own products);
(4) Copy of the export contract or order form;
(5) Where the export drug is an approved one produced by a domestic manufacturer, the Drug Manufacturing Certificate and Business License for Enterprises as a Legal Person of the manufacturer and a copy of the approval document of the drug shall be provided;
Where the export drug is produced by a domestic enterprise under contract of an overseas enterprise, the exporter shall provide a copy of the official document to prove recorded by the local (food and) drug regulatory department of the province, autonomous region and municipality directly under the Central Government.
(6) Copies of the Business License for Enterprises as a Legal Person, Qualification Certificate for Import and Export Enterprise (or Foreign Trade Operator Filing and Registration Form) and Organization Code Certificate of the exporter.

All copies mentioned above should be stamped with the official seal of the exporter.

Article 16 Where the drugs are to be shipped back in accordance with the requirements in Article 12 and Article 13 of the Provisions, the exporter shall provide the following materials to apply for the Export License for the drug:
(1) Documents proving the request for return of goods made by the original exporter of the exporting country;
(2) Import License for the drug.

Article 17 The (food and) drug regulatory department of the province, autonomous region and municipality directly under the Central Government shall decide whether or not to approve the export within 15 working days after receiving the export application and relevant materials.

Where the application is approved, the regulatory department shall issue the Export License for the drug; where the application is not approved, the regulatory department shall give reasons in writing.

Where the Export License for the drug is applied for in accordance with the requirements in Article 16 of the Provisions, the issuing authority shall mark “return of the original goods” on the Export License for the drug.

Article 18 The exporter may go through the customs formalities upon presenting the Export License for the drug issued by the (food and) drug regulatory department of the province, autonomous region and municipality directly under the Central Government. The customs shall clear the drug in the presence of the Export License for the drug.

Article 19 The importer and exporter shall provide one more sheet of customs declaration form and apply for sign-back of the sheet when going through the customs formalities. The customs shall stamp the “proof seal” on the sheet in the presence of the Import License for the drug and Export License for the drug. The customs shall charge the cost according to the relevant regulations for issuing certificates.

The importer and exporter shall return the first sheet of the Import License for the drug or Export License for the drug along with the customs declaration form with the seal of the customs, to the issuing regulatory department within one month after completing the import and export.

Where the importer or exporter conducts no relevant importation or exportation after obtaining the Import License for the drug and Export License for the drug, the importer or exporter shall return the original license to the issuing regulatory department within one month after expiration of the license.

Article 20 The validation of the Import License for the drug is one year; the validation of the Export License for the drug is no more than three months (valid within the calendar year).

“One license for one customs clearance” is implemented for the Import License for the drug and Export License for the drug. The license shall be used only once within the validation and its content shall not be altered. Where the import or export is postponed for some reasons, the importer or exporter may request for a new license once with the original one.

Article 21 Where the Import License for the drug or Export License for the drug is lost, the importer or exporter shall report the loss to the original issuing authority in writing immediately. After receiving the loss report, the original issuing authority shall notify the port customs and reissue the license if no harmful consequences are found through confirmation.

Article 22 The Import License for the drug and Export License for the drug are uniformly printed by the State Food and Drug Administration.

Article 23 Where anabolic agents and peptide hormones are imported or exported in the form of processing trade, the customs shall go through and supervise the clearance formalities upon presentation of the Import License for the drug or Export License for the drug. Those not exported for special reasons shall be transferred to and handled by the local (food and) drug regulatory department in accordance with relevant regulations, and the customs shall conduct the verification and cancellation procedures in the presence of relevant documents.

Article 24 Anabolic agents and peptide hormones entering or leaving between bonded zones, export processing zones, other special Customs controlling areas, Customs bonded and controlling areas, with overseas, or between the special Customs controlling areas and the Customs bonded and controlling areas are exempt from application for the Import License for the drug or Export License for the drug, and supervised by the Customs.

Import License for the drug shall be applied for anabolic agents and peptide hormones entering from bonded zones, export processing zones, other special Customs controlling areas and Customs bonded and controlling areas into other places in China.

Export License for the drug shall be applied for anabolic agents and peptide hormones entering bonded zones, export processing zones, other special Customs controlling areas and Customs bonded and controlling areas from other places of China.

Article 25 Where an individual carries or mails anabolic agents and peptide hormones, within a reasonable amount, into or out of China for medical needs, the customs shall clear the drugs in the presence of prescriptions of medical institutions in accordance with relevant regulations on prescriptions of the competent health department.

Article 26 Besides prescribed in the Provisions, the importation, port test, supervision and control of anabolic agents and peptide hormones for medical purpose are implemented with reference to requirements related to drug importation in the Provisions for Drug Importation.

Article 27 Anabolic agents and peptide hormones imported for medical purpose mentioned in the Provisions refer to the import anabolic agents and peptide hormones to be used for preparation production or to be marketed in China.

Importer refers to the importer specified on the Import License for the drug obtained in accordance with the Provisions.

Exporter refers to the exporter specified on the Export License for the drug obtained in accordance with the Provisions.

Article 28 These Provisions shall go into effect as of September 1, 2006. The Notice on Import and Export of Anabolic Agents and Peptide Hormones (Guo Shi Yao Jian An [2004] No. 474) issued by the State Food and Drug Administration on September 30, 2004 shall be annulled therefrom.


下载地址: 点击此处下载

关于印发《2002年全省经贸委系统法制工作要点》的通知

国家经贸委


关于印发《2002年全省经贸委系统法制工作要点》的通知

各设区市经贸委,省直属有关厅、局、集团公司:

  现将《2002年全省经贸委系统法制工作要点》印发给你们,请结合本部门实际,在工作中执行。

江西省经济贸易委员会

二OO二年四月二十三日

 

2002年全省经贸委系统法制工作要点

  2002年是我国加入世贸组织后的第一年,也是实现我省第十一次党代会提出的“以工业的崛起加速江西的崛起”的第一年。2002年,全省经贸委系统法制工作的指导思想是:以邓小平理论和党的十五大精神为指导,认真贯彻省第十一次党代会和全国经贸工作会议、全省经济、经贸工作会议精神,认真贯彻实施“依法治国,建设社会主义法治国家”的基本方略和省委、省政府制定的《江西省“十五”期间依法治省规划》,按照“三个代表”要求,紧紧围绕经贸委的中心工作,继续坚持“两个推进”,即坚持“大力推进经贸法制建设,促使经贸委机关依法行政;大力推进企业法制建设,促使企业依法经营”,认真开展全省经贸委系统经贸法制工作,不断提高经贸法制工作水平。2002年经贸法制工作的重点是:

  一、进一步做好经贸立法工作

  1.以应对加入世贸组织挑战为契机,进一步做好经贸立法工作,加快立法步伐,提高立法质量。围绕经贸委的中心工作,按照世贸组织规则要求,制定出“十五”期间省经贸委经贸立法计划。同时认真做好有关的经贸立法调研工作,加强产业结构优化升级、企业技术进步、行业管理、改善投资环境、市场流通等方面的规章制定工作。继续做好有关政府规章、规范性文件的清理修改工作。

  2.各级经贸委要紧紧围绕进一步改善全省投资环境、加速江西工业的崛起以及围绕我国加入WT0后,面临的机遇和挑战,认真做好应对措施、推进结构调整、国有企业改革与发展进程中所急需的法律问题的调研工作,提出对策建议。

  3.继续完成好各级人大、各级政府交给的立法任务。对国家经贸委、省人大法工委、省政府法制办及省直有关部门起草的有关法规、规章,认真提出修改意见和建议。

  4.建立健全经贸立法审核制度,各级经贸委起草的部门规章和重要规范性文件,都应经过法制工作部门的统一审核,以确保规章及规范性文件的合法性和规范性。

  二、大力加强和推进行政执法及执法监督工作

  以转变政府职能、改革行政审批制度为重点,进一步规范行政行为、加强行政执法及执法监督工作,提高依法行政水平。

  1.继续做好行政审批的清理和规范工作。各级经贸委要通过建章立制,形成程序严密、制约有效的行政运行机制,推进经贸工作制度化、职权行使程序化、政策措施公开化、监管工作规范化,促进各级经贸委转变职能,转变作风,依法行政,从严治政。按照国家和省政府的要求,继续做好行政审批的清理和规范工作,搞好行政审批改革工作。

  2.切实抓好行政执法和执法监督工作,逐步形成有效的工作体系。要进一步摸清经贸委系统作为主管部门负责实施的法律法规和执法权限。各级经贸委要认真落实法律、行政法规及规章赋予经贸委的执法职能,积极探索行政执法及执法监督的有效形式,保证法律法规规章的正确有效实施。要加快制定和完善省经贸委行政执法责任制和评议考核制,并进一步在全省经贸委系统推行行政执法责任制和评议考核制,不断提高经贸委系统依法行政的水平。逐步启动执法与监管工作,建立经贸委系统行政执法体制,理顺执法关系,明确执法分工,规范执法行为,加大监管力度,将行政执法工作纳入规范化的轨道。

  3.加快建立经贸委系统行政执法监督机制。各级经贸委要进一步完善行政复议制度,完善内部监督机制。研究如何提高行政执法人员的法律素质,研究统一执法的有效形式和监督机制。

  4.要积极组织对全省经贸委系统执法人员的培训,不断提高他们的执法水平和依法行政的意识和服务意识。

  三、加强企业法制工作

  1.各级经贸委要进一步深入开展调查研究,认真研究总结近年来企业法律顾问工作的经验,要将企业法律顾问工作作为加强企业管理的一项重要制度和管理方法,与建立现代企业制度和加强企业管理同步推进。年内将分片召开企业法律顾问工作经验交流会。

  2.以试行企业总法律顾问制度为切入点、大力推进企业法制建设,提高企业国际竞争力。按照国家经贸委的部署,开展企业总法律顾问试点工作。通过试点,进一步推动我省企业法律顾问制度的建立和完善,进一步建立和健全企业法律事务机构。各级经贸委要加强对这项工作的指导和协调,充分调动和发挥企业的积极性,力争今年我省有50%的国有及国有控股大中型企业设置企业法律事务机构,并配备相应的法律顾问。

  3.根据国家和省有关部门通知精神,认真组织好我省2002年全国第三批企业法律顾问执业资格考试、报名工作,并做好有关的考前培训工作。

  4.根据企业改革与发展的需要,进一步加强企业法律顾问的培训工作,要采取专题讲座、国内外学习考察等多种形式开展对企业法律顾问的培训,不断提高我省企业法律顾问队伍的整体素质。今后、我省企业法律顾问的培训要与注册工作结合起来,并形成制度。

  四、积极推动“四五”普法工作全面实施

  今年是“四五”普法的全面实施阶段,要按照国家经贸委《全国经贸委系统法制宣传教育第四个五年规划》、中共江西省委、省政府转发的《省法制宣传教育工作领导小组关于在全省公民中开展法制宣传教育的第四个五年规划》和《江西省经贸委系统法制宣传教育第四个五年规划》提出的目标和任务。制定年度普法培训计划,确定普法工作重点;明确提出要求,认真组织实施。通过“四五”普法教育,不断增强全省经贸委系统广大干部、职工,特别是各级领导干部的法制意识,提高依法行政的能力和水平。

  1.认真开展经贸委机关工作人员的普法教育。省经贸委重点抓好各设区市、县(市)经贸委主任及省经贸委处级以上干部的普法教育。各设区市经贸委要按照分工,突出重点,认真抓好本委机关和所属县(市)经贸委机关工作人员的普法教育。

  2.按照省经贸委“四五”普法规划和省委宣传部、省经贸委、省司法厅联合印发的《关于在全省企业经营管理者中推行法律素质教育的意见》要求。认真开展企业经营管理者的普法教育,省经贸委主要抓好重点企业经营管理人员的法律培训,重点学习有关WTO及企业改革发展的法律知识。各设区市经贸委要抓好所属企业经营管理人员的法律培训。各大中型企业要结合企业发展和经营实际,认真开展企业各类人员的法律知识培训。

  3.要切实加强对普法工作的领导和指导,各级经贸委、各企业要进一步建立健全机构,做到领导落实、组织落实、任务落实、责任落实。在普法工作中,要抓骨干、抓试点,以点带面,整体推进,省经贸委拟在全省选择8-10个普法重点联系单位和试点单位,各级经贸委都要选择建立3-5个普法试点单位,以典型引路,推动面上的普法工作。要认真组织好普法工作年度总结,交流普法经验,使普法任务落到实处。

  五、加强领导,进一步建立健全经贸系统法制工作机构和队伍建设

  1、加强对经贸法制工作的领导。经贸法制工作涉及面广、政策性强、工作难度大、责任重,要做好此项工作,各级领导重视尤为重要。随着改革的深入和社会主义市场经济的日趋成熟,政府职能的转变,工作方式的转变,依法管理经济显得越来越重要和紧迫,各级经贸委要加强对经贸系统法制工作的领导,进一步把法制工作真正提上领导的议事日程,高度重视法制工作、努力做到认识到位、领导到位、组织到位、措施到位。

  2、进一步建立健全经贸法制工作机构。建立健全法制机构是搞好经贸法制工作的前提。各设区市经贸委要切实建立健全法制工作机构,落实人员编制和经费。

  3、努力建设高素质的经贸法制工作队伍。做好经贸法制工作,人才是关键。要通过两支队伍的建设,做好各项经贸法制工作:一是在各级经贸委建立起一支懂法律、懂经济、专业强、素质高的经贸法制工作队伍,以促进各级经贸委逐步实现依法行政;二是在企业中建立起一支企业法律顾问队伍,重点培养一批懂法律、懂经济、懂外语的高层复合型人才,以满足企业集团化、多元化、国际化的需要,促进企业依法经营管理和依法维护自身合法权益。(完)


浙江省省级单位职工基本医疗保险暂行规定

浙江省人民政府


浙江省省级单位职工基本医疗保险暂行规定
浙江省人民政府
浙政发(2001)23号


第一章 总则
第一条 为加快实施省级单位职工基本医疗保险制度,切实保障职工基本医疗,根据《国务院关于建立城镇职工基本医疗保险制度的决定》(国发〔1998〕44号)和《浙江省推进城镇职工基本医疗保险制度改革的意见》(浙政〔2000〕5号),制定本暂行规定。
第二条 省级单位职工基本医疗保险制度改革的原则是:基本医疗保险的筹资和保障水平与经济社会发展水平相适应;基本医疗保险费由用人单位和职工共同负担,基本医疗保险的权利和义务相对应;基本医疗保险实行社会统筹和个人账户相结合。
第三条 本暂行规定适用于省级机关、群众团体、在杭省部属事业单位等单位及其职工。
应当参加基本养老保险的用人单位及其职工,在参加基本医疗保险的同时必须参加基本养老保险。
第四条 省级单位职工基本医疗保险工作由省劳动和社会保障厅统一管理,省级医疗保险服务中心具体组织实施。
省卫生、财政、地税、物价、审计、药品监管等部门应按各自的职责,协同做好基本医疗保险工作。

第二章 基本医疗保险费征缴与管理
第五条 省级单位职工基本医疗保险基金由统筹基金和个人账户组成。
省级单位职工基本医疗保险费由用人单位和在职职工共同缴纳。
(一)用人单位以本年度本单位职工工资总额为缴费基数(以下简称缴费基数),按8%的比例按月缴纳,其中6%用于建立统筹基金,2%按不同年龄计入职工个人账户。
(二)职工个人按本年度本人缴费工资2%的比例按月缴纳,由用人单位在其工资收入中代扣代缴,全部计入个人账户。
(三)职工月工资收入低于省级单位职工月平均工资60%的,按照60%确定;高于300%的,按照300%确定。
(四)省财政按年度参保单位职工工资总额的5‰给予补助(主要用于个人账户和重大疾病医疗的补助)。
退休退职人员个人不缴纳基本医疗保险费。
随着经济的发展和基本医疗保障水平的提高,经省政府批准,用人单位和职工个人的缴费比例可作相应调整。
第六条 由用人单位缴纳和提取的基本医疗保险费列支渠道:
(一)国家机关在“经常性支出”——“社会保障费”中列支。
(二)事业单位在“事业支出(经营支出)”——“社会保障费”中列支。
(三)其他用人单位在“应付福利费”中列支60%,在“劳动保险费”中列支40%。
第七条 用人单位及其职工应按规定缴纳基本医疗保险费。
(一)职工从缴费次月起享受基本医疗保险待遇。用人单位未按规定中断缴纳的,从未缴纳的次月起,其职工不再享受基本医疗保险待遇。中断缴费后要重新参加基本医疗保险的,除补足中断期间应缴纳的基本医疗保险费外,须连续缴满6个月的基本医疗保险费后,方可重新享受基本医疗保险待遇。
(二)职工在未达到法定退休年龄前,应连续参加基本医疗保险,并由用人单位和职工共同缴纳基本医疗保险费。职工到达法定退休年龄退休时,连续缴费年限不足20年的,由用人单位一次性补满20年后,可以继续享受基本医疗保险待遇。
本暂行规定实施以前职工的工作年限,按国家和省有关规定可以计算为连续工龄的,可以作为连续缴费年限计算。
第八条 基本医疗保险费由省地方税务部门负责征收。
用人单位及其职工应在每月10日前,及时足额缴纳基本医疗保险费。逾期不缴或少缴的,从滞缴之日起,每日加收应缴金额2‰的滞纳金,滞纳金并入统筹基金。
基本医疗保险费不得减免,不计征税、费。
第九条 基本医疗保险基金按下列办法计算利息:当年筹集的部分,按活期存款利率计息;上年结转的基金本息,按3个月期整存整取银行存款利率计息;存入社会保障财政专户的沉淀资金,比照3年期零存整取存款利率计息,并不低于该档次利率水平。
第十条 有关部门应当加强对基本医疗保险基金的管理和监督。
(一)医疗保险基金实行财政专户管理,专款专用,不得挤占挪用。
(二)省级医疗保险服务中心要建立健全医疗保险基金的预决算制度、支付预警报告制度、财务会计制度和内部审计制度;省级医疗保险服务中心不得从基金中提取任何费用,其所需事业经费,由省财政预算安排。
(三)省劳动保障和财政部门要加强对医疗保险基金的管理。审计部门要定期对基金收支情况和管理情况进行审计。
第十一条 用人单位应按规定向省级医疗保险服务中心办理基本医疗保险登记手续;新成立的单位应在成立之日起30日内办理基本医疗保险登记手续;用人单位新增职工,应在建立劳动(工作)关系之日起30日内办理基本医疗保险登记手续。
第十二条 省级单位职工基本医疗保险实行身份审核。
(一)省级医疗保险服务中心负责对参保职工的身份审核、认定及有关证件的发放工作。
(二)符合规定病种的职工,应持定点医疗机构的诊断证明和其他有关证明材料,向省级医疗保险服务中心提出享受规定病种门诊医疗费用支付的申请,经批准后,其规定病种门诊医疗费用可以列入统筹基金支付。
第十三条 用人单位及职工发生变更事项,应及时办理有关手续。
(一)用人单位发生变更或依法终止时,应按规定向省级医疗保险服务中心办理变更或注销登记手续。
(二)职工发生劳动(工作)关系转移及退休、死亡等,用人单位应按规定向省级医疗保险服务中心办理申报手续。
第十四条 省级医疗保险服务中心应在用人单位及其职工办理登记、变更登记等手续后,及时完成各项手续及基本医疗保险有关证件的发放或注销工作。

第三章 统筹基金与个人账户
第十五条 省级单位职工基本医疗保险的统筹基金和个人账户分开核算、分别管理,不得相互挤占。
(一)统筹基金用于支付符合基本医疗保险规定的住院及规定病种门诊医疗费用。
(二)个人账户主要用于支付在定点医疗机构发生的符合基本医疗保险规定的门诊、急诊医疗费用和统筹基金起付标准以下的医疗费用,也可以用于定点零售药店处方外配的购药费用。
职工个人账户的历年结余资金,可以用于支付按规定应由职工个人负担部分的医疗费用。
第十六条 个人账户由省级医疗保险服务中心统一建立和管理。个人缴纳的基本医疗保险费全部计入个人账户;用人单位缴费部分,根据职工不同的年龄段,按以下比例计入个人账户:
(一)35周岁以下按本人上年度本人月缴费工资(下同)的0.4%计入。
(二)35周岁至44周岁按0.7%计入。
(三)45周岁至退休退职前按1%计入。
(四)退休退职后至69周岁和70周岁以上的退休退职人员分别按上年度职工本人退休退职费(或基本养老金)的5.8%和6.8%计入;上年度本人退休退职费(或基本养老金)低于省级单位平均水平的,按平均水平的5.8%和6.8%计入。
个人账户的本金和利息为个人所有,可以结转使用和依法继承,但不得提取现金或移作他用。

第四章 基本医疗保险待遇
第十七条 统筹基金设起付标准、最高支付限额,起付标准以上至最高支付限额之间为共付段。在医疗保险结算年度内,符合基本医疗保险有关规定的住院和规定病种门诊医疗费用累计计算。
统筹基金起付标准:三级及相应医疗机构为2000元;二级及相应医疗机构为1500元;其他医疗机构为1000元。起付标准以下部分医疗费用,由个人和用人单位负担。
最高支付限额:统筹基金的最高支付限额为4万元。
共付段:共付段内的医疗费用,由统筹基金和职工个人共同支付。支付比例为:起付标准以上至2万元,在职职工统筹基金支付80%,个人自付20%;退休退职人员统筹基金支付85%,个人自付15%。2万元以上至3万元,在职职工统筹基金支付85%,个人自付15%;退休退职人员统筹基金支付90%,个人自付10%。3万元以上至4万元,在职职工统筹基金支付90%,个人自付10%;退休退职人员统筹基金支付95%,个人自付5%。建国前参加革命工作的老工人,个人自付比例在退休退职人员的基础上减半执行。
第十八条 职工在不同等级的医疗机构发生的统筹基金共付段医疗费用,实行不同的统筹基金支付比例和个人自付比例。职工在二级及相应医疗机构发生的医疗费用,其个人自付比例按第十七条规定执行;在三级及相应医疗机构发生的医疗费用,其个人自付比例按第十七条规定的120%执行;在其他医疗机构发生的医疗费用,其个人自付比例按第十七条规定的80%执行。
第十九条 职工转外地就医发生的医疗费用先由个人垫支,凭出院证明、发票和有关凭证向省级医疗保险服务中心申请报销,医疗费用先由个人自理10%后,再按第十七条规定支付。
第二十条 职工发生的规定病种门诊医疗费用,按医疗保险结算年度累计作一次住院医疗费用处理,扣除起付标准以下的医疗费用后,累计计入统筹基金共付段,按第十七条规定支付。
第二十一条 国家公务员参加基本医疗保险后,享受公务员医疗补助。
享受公务员医疗补助用人单位的职工,其门诊医疗费用和统筹基金起付标准以下的医疗费用,个人账户当年资金不足支付部分,在职职工由公务员医疗补助支付80%,个人自付20%;退休人员由公务员医疗补助支付85%,个人自付15%;建国前参加革命工作的老工人,由公务员医疗补助支付95%,个人自付5%。
第二十二条 不享受公务员医疗补助的用人单位,在参加基本医疗保险的基础上,应建立职工补充医疗保险。补充医疗保险经费在工资总额4%以内部分,先从应付福利费中列支,应付福利费不足列支的,经同级财政部门核准后可列入成本。
职工补充医疗保险经费原则上用于由用人单位和职工个人负担部分的医疗费用。职工门诊和统筹基金起付标准以下的医疗费用,先从个人账户支付,个人账户当年资金不足支付部分,由用人单位和职工共同负担,在职职工个人负担的比例为20%,原则上不超过30%;退休人员的个人负担比例为15%,原则上不超过20%;建国前参加革命工作的老工人的个人负担比例为5%。在职职工个人负担比例超过30%,退休人员超过20%的,须经职工代表大会通过并报上级工会组织备案。
第二十三条 其他有关人员的医疗待遇:
(一)离休人员、老红军的医疗待遇不变,经费按原渠道解决,支付确有困难的,由省政府帮助解决。
(二)二等乙级以上革命伤残军人的医疗待遇不变,经费按原渠道解决,不足支付时由省政府帮助解决。
(三)省、部级以上劳动模范个人承担医疗费用确有困难的,由用人单位和省财政帮助解决。

第五章 重大疾病医疗补助
第二十四条 建立重大疾病医疗补助制度。重大疾病医疗补助经费从省财政补贴中提取一部分;职工(包括退休退职人员)每人每年缴纳36元,由用人单位代扣。重大疾病医疗补助经费由省级医疗保险服务中心统一管理和支付。
第二十五条 统筹基金最高支付限额以上、符合基本医疗保险有关规定的医疗费用,职工在三级及其相应医疗机构发生的医疗费用,由重大疾病医疗补助经费支付88%,个人自付12%;在二级及其相应医疗机构发生的医疗费用,由重大疾病医疗补助经费支付90%,个人自付10%;在其他医疗机构发生的医疗费用,由重大疾病医疗补助经费支付92%,个人自付8%。
第二十六条 重大疾病医疗补助金按照基本医疗保险基金的办法申报、征缴和计息,实行财政专户管理,单独立账。

第六章 就医管理与医疗费用结算
第二十七条 省级单位职工基本医疗保险就医实行定点医疗机构及定点零售药店管理的办法。对定点医疗机构和定点零售药店实行协议管理。
省劳动保障部门会同省卫生和药品监管等部门负责定点医疗机构、定点零售药店的资格审查,省级医疗保险服务中心负责确定。
第二十八条 职工就医医疗机构的选择:
(一)职工可选择任何一家经确定的定点医疗机构就医。
(二)职工需转外地医疗机构就医的,应由转出医疗机构提出转院建议,经省级医疗保险服务中心批准。
第二十九条 职工就医时须持省级单位职工基本医疗保险专用凭证。专用凭证由省级医疗保险服务中心统一制作,用于职工就医的身份证明和门诊病情记录。
定点医疗机构在职工就医及办理住院手续时应核查其医疗保险专用凭证,发现伪造、涂改、冒用的,应予以扣存,并及时报告省级医疗保险服务中心。
第三十条 职工住院时,定点医疗机构可以向职工收取一定数额的预付款。
第三十一条 职工个人自付医疗费用的结算:
(一)职工发生不符合基本医疗保险有关规定的医疗费用,由定点医疗机构和定点零售药店直接向职工收取。
(二)职工发生符合基本医疗保险规定应当由个人自付部分的医疗费用,由定点医疗机构和定点零售药店直接向职工收取;符合个人账户支付范围的,也可以由其个人账户支付。
第三十二条 基本医疗保险统筹基金支付的医疗费用的结算:
(一)应由统筹基金支付的医疗费用由定点医疗机构及定点零售药店按月向省级医疗保险服务中心结算。
(二)省级医疗保险服务中心应对申报的医疗费用进行审核。对结算申请中不符合基本医疗保险统筹基金支付范围的医疗费用不予支付。
(三)职工定居外地或长驻外地工作,在住地附近的医疗机构住院及规定病种门诊发生的医疗费用,符合规定的,可以列入统筹基金支付范围。
(四)个人账户支付的医疗费用,由定点医疗机构及定点零售药店按月向省级医疗保险服务中心结算。不符合规定的医疗费用不予支付。

第七章 违反基本医疗保险有关规定的责任
第三十三条 用人单位出现下列情况的,按《社会保险费征缴暂行条例》的有关规定处理:
(一)未按规定办理基本医疗保险参保手续,或者未按规定申报应缴纳的基本医疗保险费数额的。
(二)违反财务、会计、统计的有关规定,伪造、变造、故意销毁有关账册、材料,或者不设账册,致使基本医疗保险缴费基数无法确定的。
(三)违反有关规定延迟缴纳基本医疗保险费的。
(四)违反国家和省规定的其他情况的。
第三十四条 个人不符合享受基本医疗保险待遇条件,以弄虚作假、冒名顶替等手段骗取医疗费和其他医疗保险待遇的,由省劳动保障行政部门责令退还相应费用;参保职工发生上述情形,情节严重的,由省级医疗保险服务中心收回基本医疗保险专用凭证,暂停享受基本医疗保险待遇。
第三十五条 定点医疗机构、定点零售药店及其工作人员违反规定造成基本医疗保险基金损失的,省级医疗保险服务中心应向定点医疗机构、定点零售药店追回损失费用,由省劳动保障部门视情节给予警告、责令限期整改、暂停或取消其定点资格。
第三十六条 有关部门出现以下情形的,按《社会保险费征缴暂行条例》的有关规定处理:
(一)单位、个人挪用基本医疗保险基金的。
(二)基本医疗保险有关管理部门和经办机构工作人员滥用职权、徇私舞弊、玩忽职守,造成医疗保险费流失的。
(三)其他违反国家和省规定行为的。

第八章 附则
第三十七条 以下情形不属于省级单位职工基本医疗保险基金支付的范围:
(一)不属于基本医疗保险支付范围内的医疗费用。
(二)职工在非定点医疗机构就医、购药或在非定点零售药店购药发生的医疗费用。
(三)属于工伤、生育保险支付范围内的医疗费用。
(四)职工因自杀、自残、斗殴、吸毒、违法犯罪及医疗、交通事故等所发生的医疗费用。
(五)不可抗拒的大规模自然灾害、大规模暴发性传染病引起的非正常医疗费用,由省政府研究解决。
(六)国家和省另有规定的其他医疗费用。
第三十八条 省级单位职工平均工资按国家统计局列入工资总额统计的项目计算,由省有关部门核准。
第三十九条 省劳动保障部门可会同省财政、卫生部门根据本暂行规定制定实施细则。
第四十条 本暂行规定自二○○一年四月一日起实施。


2001年3月31日

版权声明:所有资料均为作者提供或网友推荐收集整理而来,仅供爱好者学习和研究使用,版权归原作者所有。
如本站内容有侵犯您的合法权益,请和我们取得联系,我们将立即改正或删除。
京ICP备14017250号-1